234 related articles for article (PubMed ID: 23661240)
1. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study.
Horwitz MJ; Augustine M; Khan L; Martin E; Oakley CC; Carneiro RM; Tedesco MB; Laslavic A; Sereika SM; Bisello A; Garcia-Ocaña A; Gundberg CM; Cauley JA; Stewart AF
J Bone Miner Res; 2013 Nov; 28(11):2266-76. PubMed ID: 23661240
[TBL] [Abstract][Full Text] [Related]
2. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF
J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
[TBL] [Abstract][Full Text] [Related]
3. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
4. A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.
Horwitz MJ; Tedesco MB; Sereika SM; Prebehala L; Gundberg CM; Hollis BW; Bisello A; Garcia-Ocaña A; Carneiro RM; Stewart AF
J Bone Miner Res; 2011 Sep; 26(9):2287-97. PubMed ID: 21544866
[TBL] [Abstract][Full Text] [Related]
5. Serum parathyroid hormone is associated with increased cortical porosity of the inner transitional zone at the proximal femur in postmenopausal women: the Tromsø Study.
Osima M; Borgen TT; Lukic M; Grimnes G; Joakimsen RM; Eriksen EF; Bjørnerem Å
Osteoporos Int; 2018 Feb; 29(2):421-431. PubMed ID: 29134242
[TBL] [Abstract][Full Text] [Related]
6. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women.
Pereda CA; Hannon RA; Naylor KE; Eastell R
BJOG; 2002 Jul; 109(7):812-20. PubMed ID: 12135219
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.
Horwitz MJ; Tedesco MB; Garcia-Ocaña A; Sereika SM; Prebehala L; Bisello A; Hollis BW; Gundberg CM; Stewart AF
J Clin Endocrinol Metab; 2010 Mar; 95(3):1279-87. PubMed ID: 20061412
[TBL] [Abstract][Full Text] [Related]
8. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
Kharroubi A; Saba E; Smoom R; Bader K; Darwish H
Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
Black DM; Bouxsein ML; Palermo L; McGowan JA; Newitt DC; Rosen E; Majumdar S; Rosen CJ;
J Clin Endocrinol Metab; 2008 Jun; 93(6):2166-72. PubMed ID: 18349061
[TBL] [Abstract][Full Text] [Related]
10. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
[TBL] [Abstract][Full Text] [Related]
11. Calciotropic Hormones and the Prevalence of Vertebral Fractures in Chinese Postmenopausal Women with Vitamin D Insufficiency: Peking Vertebral Fracture Study.
Jiajue R; Jiang Y; Qi X; Wang Q; Wang W; Pei Y; Wang X; Huang W; Zheng X; Ning Z; Wang O; Li M; Xing X; Yu W; Xu L; Xia W
Calcif Tissue Int; 2019 Jun; 104(6):622-630. PubMed ID: 30737534
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
[TBL] [Abstract][Full Text] [Related]
13. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.
Hansen KE; Nieves JW; Nudurupati S; Metz DC; Perez MC
Gastroenterology; 2019 Mar; 156(4):926-934.e6. PubMed ID: 30445008
[TBL] [Abstract][Full Text] [Related]
14. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.
Plotkin H; Gundberg C; Mitnick M; Stewart AF
J Clin Endocrinol Metab; 1998 Aug; 83(8):2786-91. PubMed ID: 9709948
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.
Horwitz MJ; Tedesco MB; Sereika SM; Garcia-Ocaña A; Bisello A; Hollis BW; Gundberg C; Stewart AF
Osteoporos Int; 2006 Feb; 17(2):225-30. PubMed ID: 16151606
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
17. Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, six-month, phase 2 study.
Tripto-Shkolnik L; Szalat A; Tsvetov G; Rouach V; Sternberg C; Hoppe A; Burshtein G; Galitzer H; Toledano M; Harari G; Santora AC; Cosman F
J Bone Miner Res; 2024 Apr; ():. PubMed ID: 38578978
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective.
Kuchuk NO; van Schoor NM; Pluijm SM; Chines A; Lips P
J Bone Miner Res; 2009 Apr; 24(4):693-701. PubMed ID: 19049341
[TBL] [Abstract][Full Text] [Related]
19. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
20. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
